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ABSTRACT
Loss of the tumor suppressor merlin causes development of
the tumors of the nervous system, such as schwannomas,
meningiomas, and ependymomas occurring spontaneously
or as part of a hereditary disease Neurofibromatosis Type 2
(NF2). Current therapies, (radio) surgery, are not always
effective. Therefore, there is a need for drug treatments for
these tumors. Schwannomas are the most frequent of mer-
lin-deficient tumors and are hallmark for NF2. Using our
in vitro human schwannoma model, we demonstrated that
merlin-deficiency leads to increased proliferation, cell–ma-
trix adhesion, and survival. Increased proliferation due to
strong activation of extracellular-signal-regulated kinase 1/
2 (ERK1/2) is caused by overexpression/activation of plate-
let-derived growth factor receptor-b (PDGFR-b) and ErbB2/
3 which we successfully blocked with AZD6244, sorafenib,
or lapatinib. Schwannoma basal proliferation is, however,
only partly dependent on PDGFR-b and is completely inde-
pendent of ErbB2/3. Moreover, the mechanisms underlying
pathological cell–matrix adhesion and survival of schwan-
noma cells are still not fully understood. Here, we demon-
strate that insulin-like growth factor-I receptor (IGF-IR) is
strongly overexpressed and activated in human primary
schwannoma cells. IGF-I and -II are overexpressed and
released from schwannoma cells. We show that ERK1/2 is
relevant for IGF-I-mediated increase in proliferation and
cell–matrix adhesion, c-Jun N-terminal kinases for
increased proliferation and AKT for survival. We demon-
strate new mechanisms involved in increased basal prolifer-
ation, cell–matrix adhesion, and survival of schwannoma
cells. We identified therapeutic targets IGF-IR and down-
stream PI3K for treatment of schwannoma and other mer-
lin-deficient tumors and show usefulness of small molecule
inhibitors in our model. PI3K is relevant for both IGF-IR
and previously described PDGFR-b signaling in schwan-
noma. VC 2012 Wiley Periodicals, Inc.
INTRODUCTION
Deficiency of the tumor suppressor merlin causes
spontaneous schwannomas, meningiomas, and ependy-
momas, which are also a feature of a hereditary disease
neurofibromatosis Type 2 (NF2). Merlin belongs to Ezrin–
Radixin–Moesin protein family (Rouleau et al., 1993) and
regulates growth factor receptor signaling (Ammoun and
Hanemann, 2011; McClatchey and Fehon, 2009). Schwan-
nomas are the hallmark of NF2 and the most frequent of
the merlin-deficient tumors for which we aim to define
new therapeutic targets. Using our in vitro human
schwannoma model (Rosenbaum et al., 1998), we have
previously shown overexpression/activation of ErbB2/
ErbB3 (Ammoun et al., 2010a) and platelet-derived
growth factor receptor (PDGFR) (Ammoun et al., 2008) in
human primary schwannoma cells and tissues resulting
in increased activity of extracellular-signal-regulated ki-
nase (ERK1/2) and AKT and enhanced proliferation
(Ammoun et al., 2008, 2010a,b). PDGFR-b is important in
schwannoma proliferation (Ammoun et al., 2008, 2010a)
but not cell–matrix adhesion (Ammoun et al., 2008), an
important characteristic of schwannoma (Flaiz et al.,
2009a; Utermark et al., 2003b). Moreover, increased basal
(nonstimulated) proliferation of schwannoma cells is only
partly dependent on PDGFR-b (Ammoun et al., 2008) and
is not responsive to ErbB2/ErbB3 inhibitors (Ammoun
et al., 2010a), suggesting the involvement of additional
factors. Ras is strongly activated in schwannoma involved
only in basal (nonstimulated) ERK1/2 signaling independ-
ently on PDGFR (Ammoun et al., 2008). Lallemand et al.
(2009) found that membrane accumulation of receptor ty-
rosine kinases is regulated by merlin. In addition to plate-
let-derived growth factors (PDGFs), insulin-like growth
factors I/II (IGF-I/II) are relevant in rodent Schwann cells
(Meier et al., 1999). IGF-I stimulates myelination in
Schwann cells via the PI3K/AKT pathway (Ogata et al.,
2004), control cell–matrix adhesion, proliferation, and
survival (Meier et al., 1999; Schumacher et al., 1993) via
ERK1/2 (Duan, 2003), AKT, focal adhesion kinase (FAK),
and c-Jun N-terminal kinases (JNK) (Walsh et al., 2002)
which are all strongly activated in schwannoma
(Ammoun et al., 2008; Kaempchen et al., 2003). We there-
fore investigated the role of the IGF/IGF-IR system in
proliferation, cell–matrix adhesion, and survival of
human primary schwannoma cells. We show overexpres-
sion and activation of IGF-IR and overexpression and
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release of IGF-I and IGF-II from schwannoma cells.
IGF-IR triggers ERK1/2, AKT, JNK, and FAK phosphoryl-
ation/activation in schwannoma cells. We analyzed signal-
ing pathways and showed that ERK1/2 is relevant for
IGF-I-mediated increase in proliferation and adhesion,
JNK for increased proliferation and AKT for survival. We
suggest that, in addition to PDGFR (Ammoun et al., 2008,
2010a) and ErbB2/ErbB3 (Ammoun et al., 2010a), the
IGF-system is important for schwannoma pathobiology.
This is a novel observation broadening our knowledge
about the pathobiology of schwannoma and other merlin-
deficient tumors. Importantly, our findings have a future
therapeutic relevance as using a small molecule PPP and
monoclonal antibody R1507, we successfully inhibited
IGF-R-mediated proliferation of human primary schwan-
noma cells. We also identified PI3K as a common target
for IGF-IR and PDGFR, which when inhibited would
block signaling mediated by both receptors.
MATERIALS AND METHODS
Culture of Human Primary Schwann and
Schwannoma Cells
Human primary Schwann and schwannoma cells were
isolated as described in our previous work (Rosenbaum
et al., 1998). The study was approved by our Institu-
tional Review Board. Schwann cells were isolated from
peripheral nerves obtained from multiorgan donors not
carrying any neurological disease after informed con-
sent. Schwannomas were kindly provided by NF2
patients after informed consent. Diagnosis of NF2 was
based on clinical criteria defined by the NIH Consensus
Conference on Neurofibromatosis. Human malignant
mesothelioma cell lines; merlin-deficient mesothelioma
cell line (TRA) and merlin-expressing mesothelioma
(HIB) were used as controls (Utermark et al., 2003a).
Cells were cultured in complete medium (Growth Factor
Medium): DMEM, 10% FCS, 0.5 lM forskolin, 10 nM b
heregulin, 0.5 mM 3-isobutyl-1-methylxanthine, and 2.5
lg/mL insulin. For each experiment, samples from
three-six different patients were used. Merlin expression
was detected by western blotting using antimerlin anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA). For
every assay, tumors from three different patients were
used. No discrepancies in the results between patients
were observed. For proliferation assay, all the cells from
different tumors were in early passages (1–2) as older
passages displayed slower growth rate.
Inhibitors and Chemicals
GF109203X was from Tocris Bioscience (Bristol, UK).
SU6656, FTI-277, and PPP were from Calbiochem (La
Jolla, CA). R1507 was from Roche (Basel, Switzerland).
SP600125 was from Affiniti, Wortmannin from Tocris,
BEZ-235 from Novartis (Horsham, UK), short hairpin
RNA (shRNA) FAK and IGF-IR from Open Biosystems
(Huntsville, AL). DAPI and propidium iodide were from
Sigma (St. Louis, MO) and MEK1/2 inhibitor U0126 (Du
et al., 2010) from Promega (Madison, WI). Anti-FLAG
tag antibodies were from Sigma and adenovirus express-
ing FLAG-tagged JNK-binding domain (JBD) of JNK-
interacting protein-1 (JIP-1) (Harding et al., 2001) was a
gift from Dr, Parkinson (Parkinson et al., 2004). IPA3
(‘‘inhibitor targeting PAK1 activation’’ 2,20-dihydroxy-
1.10-dinaphthylsulfide) (20 lM) (Flaiz et al., 2009b) and
the control PIR-3.5 (‘‘PAK1 inhibitor relative 3.5’’ 2-
naphthalenol-6,60-dithiobis) (20 lM) (Flaiz et al.,
2009a,b) were gifts from J. Peterson, Philadelphia.
Human recombinant-IGF-I was from Cell Sciences
(Canton, MA) and Sigma and -IGF-II from Sigma. IGF-I
and 2II were used at a concentration of 100 ng/mL
(Fiedler et al., 2006; Zhang et al., 2009). Most of these
drugs have been previously tested in our human pri-
mary schwannoma model (Ammoun et al., 2008, 2010a;
Flaiz et al., 2009b). PNGase F was from New England
Biolabs (Herts, UK), and removal of carbohydrate resi-
dues was performed according to manufacturer instruc-
tions. For western blotting and proliferation assays all
inhibitors were used at concentrations within their spec-
ificity and working concentration range which have been
previously confirmed by others (Bennett et al., 2001; Du
et al., 2010; Georgakis et al., 2006; Rexhepaj et al.,
2010; Sakai et al., 2010; Toullec et al., 1991). FTI277
was used at higher concentration (30 lM) which inhibits
all Ras subfamilies as confirmed by the manufacturer
and other scientific articles (Kim et al., 2010; Lerner
et al., 1995) and have been previously shown by us to in-
hibit Ras and basal but not PDGFR-mediated activity of
ERK1/2 in schwannoma (Ammoun et al., 2008). U0126,
SU6656, and wortmannin have been previously vali-
dated for human primary schwannoma cells (Ammoun
et al., 2008, 2011, 2012). Concentration titration was
done for SP600125 (data not shown), and R1507 as their
starting concentrations were not effective. For survival
assays, U0126 and SP600125 were used at much higher
concentrations than their IC50, however without any
effect. FAK and IGF-IR, shRNA, was used in addition to
chemical inhibitors. For JNK inhibition, adenovirus
expressing FLAG-tagged JBD of JIP-1 was used in addi-
tion to the chemical inhibitor. For PI3K and IGF-IR, two
different inhibitors were used for data confirmation.
shRNA Knockdown
GIPZ-shRNAmir lentiviral particles encoding a
shRNA with nonsilencing sequence (mock) or sequences
targeting specific genes, including human FAK
(V2LHS_57326) and human IGF-IR (ready to use GIPZ
viral particles, V2LHS_131070) were used. (1) Cells
were seeded into 6-well plate to reach 70% confluence
(Day 1); (2) cells were infected with 2.5ll virus per well
in the full growth media containing 8 lg/mL protamine
sulfate (Day 2); (3) growth media were replaced, 4 lg/
mL puromycin was added into media for 48 h (Day 3).
The knock down efficiency of each clone against nonsi-
lencing control was verified by western blotting.
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Reintroduction of Merlin
Mock (control adenovirus containing a GFP) and mer-
lin wild type (recombinant adenovirus AdNF2) were gift
from J. Testa (Xiao et al., 2005). Cells were infected for 24
h followed incubation with fresh GFM for additional 24 h.
Immunoblotting
Electrophoresis/western blotting (Kaempchen et al.,
2003) were performed using antiphospho-IGF-I receptor
Tyr1158/1162/1163 (Abcam, Cambridge, MA), antiactive-
MAPK (anti-pThr(183)-pTyr (185)-ERK1/2) (Promega),
antiphospho-AKT (Ser473) (Cell Signaling, Danvers,
MA), antiphospho-FAK (Tyr925) (Cell Signaling), anti-
phospho-FAK (Tyr397) (Chemicon International, Teme-
cula, CA), antiphospho-FAK (Tyr861) (Stressgen, New
York, NY), antiphospho-JNK (Thr183/Tyr185) (Cell
Signaling), anti-human-IGF-I (Abcam) and anti-human-
IGF-II (Abcam and R&D Systems, Minneapolis, MN),
anti-human-IGF-I-receptorb (Cell Signaling), anti-
human-IGF-II-receptor (R&D Systems), anti-FAK (Mili-
pore, Watford, UK), and HRP-conjugated secondary
antibodies (Biorad, Hercules, CA). ECL-plus (Amersham,
Buckinghamshire, UK) was used for detection. Anti-Src
(Cell Signaling), anti-AKT (Santa Cruz Biotechnology),
anti-JNK1/2, and anti-ERK1/2 (Cell Signaling) were
used to monitor total protein amount. Because short-
term stimulations (10 min) do not affect protein expres-
sion levels (Lee et al., 2007), we have used a generic
loading control Rho-GDI previously established for our
system and which expression is not deregulated in
schwannoma cells (Anti-RhoGDI antibody; Santa Cruz
Biotechnology) (Hanemann et al., 2006). Actin or tubulin
are not appropriate loading controls as schwannoma cy-
toskeleton is deregulated (Flaiz et al., 2009a,b). In some
experiments, total protein was used for loading control
which correlated with RhoGDI. In one experiment,
GAPDH (Milipore) was used as a loading control.
Images were scanned and processed using Corel Paint
Shop Pro Photo XI software. Images represent the
original data. The membranes were stripped after each
probing, blocked and reprobed with new antibody. The
stripping effectiveness was determined by using second-
ary antibody and developing.
Immunohistochemistry
Following 30 min blocking of endogenous peroxidase
with 3% hydrogen peroxide, 4lm paraffin sections of for-
malin-fixed schwannoma tissues were pretreated with
citrate buffer (pH 6) in a microwave for 30 min (Hane-
mann et al., 1997; Korinthenberg et al., 1997). Sections
were counterstained with hematoxylin. Parallel section
where stained with hematoxylin and eosin and showed
no evidence of necrosis. Antibodies were applied over-
night: antiphospho-IGF-I receptor Tyr1158/1162/1163
(Abcam), IGF-I (Abcam), and IGF-II (Abcam). Detection
was performed with the Vectastain Universal Elite ABC
kit (Vector Laboratories, Peterborough, UK). Controls
were by omission of the primary antibody. Some sections
were incubated with k phosphatase (8,00,000 U/mL, at
30C for 2 h New England Biolabs, Hitchin, UK).
Immunocytochemistry
The cells were fixed, permeabilized, and blocked as
described (Flaiz et al., 2009a,b; Kaempchen et al., 2003).
Localization of IGF-I was performed using anti-human-
IGF-I (Abcam). Alexa Fluor 488-labeled phalloidin was
used to visualize actin filaments (1:100; Molecular
Probes, Eugene, OR). Multitrack imaging was performed
using a Zeiss Confocal LSM510. Blocking peptide (BP)
was used to demonstrate staining specificity.
Blocking of Primary Antibodies
0.4 lg/mL anti-human-IGF-I and -IGF-II antibodies
were incubated with 5-fold excess of BP at 37C for 2 h,
then overnight at 4C. Samples were centrifuged at
14,000 rpm/15 min/4C. Supernatants were diluted in
1% BSA/TBS.
RNA Extraction and RT-PCR
Total RNA was extracted from schwannoma cells from
4 different patients using GenEluteTM Mammalian Total
RNA Miniprep Kit (Sigma) and treated with DNA-freeTM
Kit (Ambion, Huntingdon, UK) according to the manu-
facturers’ instructions. Total RNA from muscle and liver
were from Clontech (Saint-Germain-en-Laye, France).
0.5 lg of total RNA from each sample was reverse tran-
scribed using the High Capacity cDNA Archive Kit
(Ambion) according to manufacturer’s instructions.
Conditions for the PCR amplification of cDNA were:
denaturation at 95C 15 s, annealing at 55C 60 s, and
extension at 72C 30 s for 40 cycles (Table 1).
Cell Growth and Viability
Cells were cultured as described (Ammoun et al., 2008)
for 24 h under different conditions: DMEM, 100 ng/mL
human recombinant-IGF-I, 100 ng/mL human recombi-
nant-IGF-II or GFM. BrdUrd incorporation was per-
TABLE 1. Primer Sequences for IGF Precursors
Primer name Sequence (50–30) Product size (bp)
IA Fw AGGTGAAGATGCACACCATG 430
IA Rev CTGCACTCCCTCTACTTGC
IIA Fw CTACAGTGAAGATGCACACC 380
IIA Rev CTGCACTCCCTCTACTTGC
IB Fw GTATGGCTCCAGCAGTCG 240
IB Rev GGATGTGTCTTTGGCCAAC
IC Fw GTATGGCTCCAGCAGTCG 222
IC Rev CCTTCTCTGAGACTTCGTG
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formed as described in Ammoun et al. (2006) using anti-
BrdUrd antibody (Calbiochem) and ALEXA-Fluor488 la-
beled secondary antibody (Molecular Probes/Invitrogen,
Paisley, UK). For JNK inhibition, schwannoma cells were
preincubated in defined medium (Morgan et al., 1994) for
1 h before infection with GFP control or JBD-expressing
adenovirus. After 24 h, medium was changed to DMEM,
and cells were stimulated with IGF-I (100 ng/mL) for
additional 24 h. Infection efficiency was determined by
anti-FLAG tag primary (Sigma) and ALEXA-Fluor488
labeled secondary antibodies (Sigma). Inhibitors were
added 40 min before stimulation. Total cell number was
determined by DAPI (1 lg/mL) and cell viability by propi-
dium iodide (2.5 lg/mL).
Adhesion Assay
Adhesion assay was performed as described in Uter-
mark et al. (2003b). Cells were stimulated with 100 ng/
mL human recombinant-IGF-I or IGF-II or with GFM.
Inhibitors were added 40 min before stimulation.
Data Analysis
Student’s two-tailed t tests and ANOVA were used. All
experiments were repeated at least three times using at
least three independent batches of cells from different
individuals. ns (not significant): P > 0.05; *: P < 0.05; **:
P < 0.01; ***: P < 0.001. In figures, mean6 SEM is given.
RESULTS
IGF-IR is Strongly Overexpressed, Glycosylated,
and Activated in Schwannoma
Primary human schwannoma cells (NF22/2) strongly
overexpress IGF-IR compared with normal human
Schwann cells (NF21/1) (Fig. 1a) which is reversed by
merlin reintroduction suggesting direct correlation
between merlin and receptor expression (Fig. 1b). IGF-IR
is strongly phosphorylated, in basal (nonstimulated) con-
ditions, in schwannoma cells compared with normal
Schwann cells (Fig. 1c) which is potentiated by recombi-
nant 100 ng/mL IGF-I (Fig. 1d) and reversed by merlin
reintroduction (Fig. 1e). Human schwannoma tissues
(Fig. 1f first panel) also showed strong cytoplasmic and
nuclear staining of phosphorylated IGF-IR compared
with three normal nerve biopsies, which displayed only
weak nuclear and almost no cytoplasmic staining (Fig. 1f
third panel). Staining was performed on schwannomas
from five different patients and showed fairly uniform
cytoplasmic immunoreactivity throughout the tumors,
but variable nuclear staining (Fig. 1f first panel and
Supp. Info. Fig. 4a). Nuclear localization of IGF-IR corre-
lates with receptor’s tumorigenicity previously shown in
other tumors (Sehat et al., 2010). Pretreatment of tissue
with phosphatase decreased signal intensity (Fig. 1f mid-
dle picture). Additionally human merlin-deficient meso-
thelioma cells (TRA) express IGF-IR at 10 times higher
levels than merlin-expressing mesothelioma (HIB) cells
(Fig. 1g) used as a control for merlin-mediated pathologi-
cal changes. IGF-IR is glycosylated (Fig. 1h). No differ-
ence in glycosylation intensity between Schwann and
schwannoma cells was observed (Fig. 1h). IGF-IIR is
equally expressed in Schwann and schwannoma cells
(Fig. 1i first panel) and reintroduction of merlin did not
affect IGF-IIR expression (Fig. 1i second panel).
IGF-I and IGF-II are Strongly Overexpressed
and Released in Schwannoma
IGF-I (Fig. 2a,c) and IGF-II (Fig. 2d) are strongly
overexpressed in schwannoma cells (NF22/2) detected
by western blotting. Strong overexpression of IGF-I pre-
cursor was also observed (Fig. 2b,c) as for mature IGF-I.
The presence of three IGF-I precursor isoforms IGF-I
IA, 2IIA, and 2IC, but not 2IB were detected by PCR
in schwannoma cells (Supp. Info. Fig. 1). Only merlin-
deficient human schwannoma (NF22/2) and human
merlin-deficient mesothelioma (TRA) (Fig. 2e,f,h) but not
human merlin-expressing mesothelioma (HIB) cells over-
expressed IGF-I or precursor isoforms. Cell lines were
used to confirm the role of merlin-deficiency in the
abnormalities investigated. IGF-II is overexpressed in
human schwannoma cells (NF22/2) (Fig. 2g,h). The
expression of IGF-I precursor, mature IGF-I, and IGF-II
are decreased on merlin reintroduction (Fig. 2i–k).
Schwannoma cells released IGF-I and IGF–II into the
media at higher levels than Schwann cells, detected by
western blotting in cell culture media on 24 h starvation
(Fig. 2l,m), suggesting a possibility for autocrine signal-
ing. Specificity of IGF-I and IGF-II bands were exam-
ined using BPs (Fig. 2l,m bottom panels). As total pro-
tein levels detected by Ponsceau S directly correlated
with the intensity of nonspecific general bands on IGF-I/
II probing (Supp. Info. Fig. 2 and previous publications
Ammoun et al., 2011), we normalized to the later. Gen-
eral bands were used as loading control for western
blots on cell culture media as there is are no known
loading markers in media. In Fig. 2l, m bottom panels
recombinant IGF-I and IGF-II peptides alone were
loaded on gels to monitor the specificity of BPs and cor-
rect molecular weight of proteins detected in culture
media. Nuclear and cytoplasmic localization of IGF-I
and IGF-II was observed in schwannoma tissues (n 5 5;
Fig. 2n bottom first and second panels) (Schedlich et al.,
2003). Normal tissues expressed IGF-I and IGF-II
weaker (n 5 4; Fig. 2n upper first and second panels).
Staining for IGF-I and IGF-II was fairly uniform
throughout the tissues observed in tumors from five dif-
ferent patients, although there was some variation with
nuclear immunoreactivity, and in the case of IGF-II,
cytoplasmic intensity (Fig. 2n bottom first and second
panels and Supp. Info. Fig. 4b,c). Immunocytochemistry
demonstrates a specific IGF-I staining in the nucleus
and cytoplasm in schwannoma cells (Fig. 2o first
picture). BP was used to confirm staining specificity
(Fig. 2o second picture).
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Dissection of IGF-I-Mediated Signaling Pathways
in Human Primary Schwannoma Cells
IGF-I stimulation of schwannoma cells leads
to strong phosphorylation of FAK at Tyr925
and Src at Tyr416 and strongly activates
ERK1/2, AKT, and JNK
Autophosphorylation of FAK at Tyr397 and Src-
mediated phosphorylation at Tyr861 were not increased
(Fig. 3a,c). IGF-I (100 ng/mL, 5 min) (Fiedler et al.,
2006) strongly phosphorylated FAK at Src phosphoryla-
tion site Tyr925 (Fig. 3b; n 5 3). Accordingly, Src was
phosphorylated by IGF-I (100 ng/mL, 5 min) at Tyr416
(Fig. 3d; n 5 3). IGF-I (100 ng/mL, 5 min) potentiated
basal ERK1/2 (Fig. 3e), AKT (Fig. 3f; n 5 3), and JNK
(Fig. 3g; n 5 3) activity in primary human schwannoma
cells. Total levels of FAK, Src, ERK1/2, AKT, and JNK
were unaffected (Fig. 3b,e,f, g; n 5 3).
IGF-IR-mediated activation of ERK1/2
engages Src/FAK/Ras/PI3K/PKC, JNK Src/FAK/
Ras/PI3K/PKC/PAK, and AKT Ras/PI3K/PAK
pathways
To elucidate the signaling pathways involved in IGF-IR
mediated activation of AKT, ERK1/2, and JNK in
schwannoma cells (NF22/2), we used shRNA for IGF-IR
Fig. 1. IGF-I/II receptors’ expression, activation, and glycosylation
in merlin-positive/deficient cells. (a) IGF-IR is strongly overexpressed
in schwannoma cells (NF22/2) compared with Schwann cells (NF21/
1). (b) IGF-IR overexpression is reversed by the reintroduction of wild
type merlin (wt, n 5 4), but not the mock (control adenovirus contain-
ing a GFP). (c) Phosphorylated IGF-IR (P-IGF-IR) is strongly expressed
in schwannoma cells (NF22/2) in basal (nonstimulated) conditions (n
5 5), (f) and in human schwannoma tissues (n 5 5, first panel) com-
pared with normal tissues (NF21/1) (n 5 4, third panel). (d) IGF-IR
phosphorylation is increased on stimulation of schwannoma cells with
recombinant IGF-I (100 ng/mL) compared with Schwann cells (NF21/
1), (e) which is reversed by reintroduction of merlin. (g) IGF-IR is over-
expressed in merlin-deficient human mesothelioma (TRA, n 5 4) but
not merlin-positive human mesothelioma (HIB, n 5 4). (h) IGF-IR is
glycosylated in both schwannoma and Schwann cells. Cells were
treated with or without glycosidase then checked with anti-IGF-IR anti-
body. (i) IGF-IIR is equally expressed in both schwannoma and
Schwann cells (n 5 3; first panel) independently on merlin expression
(second panel). In (c), (d), and (e), the cells were starved for 24 h, in (c)
cells were lysed directly and in (d) and (e) stimulated with IGF-I (100
ng/mL) for 5 min before lysing. In (a), (c), and (i), the data are normal-
ized to NF21/1. In (b), the data are normalized to the basal levels
(nonstimulated) and in (g) to HIB. In (b) and (e), the data are normal-
ized to mock adenovirus infected cells. Experiments in (d) were run in-
dependently on different gels therefore only the ratio basal versus IGF-
I stimulated signal could be compared within the same cell type and
different cell types. Basal activities between cell types could not be
compared. RhoGDI served as a control and Western blotting were quan-
tified. ns (not significant): P > 0.05; *: P < 0.05; **: P < 0.01; ***: P <
0.001. In figures, mean 6 SEM is given. [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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Fig. 2. Expression and release of IGF-I and IGF-II in human pri-
mary schwannoma cells. (a) IGF-I, (b) and (c) IGF-I precursors (n 5 7)
and (d) IGF-II (n 5 6) are overexpressed in schwannoma cells (NF22/
2) compared with normal Schwann cells (NF21/1, n 5 5). (e, f, and h)
Mature and precursor IGF-I are overexpressed in merlin-deficient
schwannoma (NF22/2, n 5 7) and merlin-deficient mesothelioma
(TRA, n 5 4) cells compared with Schwann cells (NF21/1, n 5 5) and
human merlin-positive mesothelioma (HIB, n 5 4). (g and h) IGF-II is
expressed strongest in merlin-deficient schwannoma (NF22/2, n 5 6)
cells. (i–k) Reintroduction of wild type merlin (wt), but not mock control
(GFP only) into schwannoma cells (NF22/2) decreases intracellular
expression of mature IGF-I (i and k, n 5 5), IGF-I precursor (i and k, n
5 4) and IGF-II (i and j, n 5 5). Band in (k) mock is caused due to spill
over of the lysates. (l and m) Increased release of IGF-I (l, n 5 5) and
IGF-II (m, n 5 3) from schwannoma cells compared with Schwann cells
(n 5 5 for IGF-I and n 5 3 for IGF-II). Specificity of antibodies is dem-
onstrated in the bottom panels using blocking peptides. Cells were cul-
tured in serum-free medium (DMEM) for 24 h, medium was collected
and IGF-I/II detected by western blotting. Unspecific bands served as
control. (n) shows that IGF-I and IGF-II are strongly expressed in vivo
in schwannoma tissues (NF22/2) (n 5 5) compared with normal tis-
sues (NF21/1) shown by immunohistochemistry, scale bar 5 50 lm (n
5 4). (o) shows, by immunocytochemistry, a specific nuclear localization
of IGF-I (left picture) which was abrogated with blocking peptide (BP)
(right picture). In (a), (d), (l), and (m), the data are normalized to
NF21/1, in (e), (f), and (g) to NF22/2 and in (i) to mock adenovirus
infected cells. ns (not significant): P > 0.05; *: P < 0.05; **: P < 0.01;
***: P < 0.001. In figures, mean 6 SEM is given. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.
com.]
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and FAK (Supp. Info. Fig. 3a,b) and various inhibitors
previously established in our model and by others in the
concentrations described (Ammoun et al., 2008; Du et al.,
2010; Duggan et al., 2007; Flaiz et al., 2009b; Georgakis
et al., 2006; Kim et al., 2010; Momcilovic et al., 2008;
Rexhepaj et al., 2010; Sakai et al., 2010; Shi et al., 2001).
Activity of AKT, ERK1/2, and JNK were investigated
simultaneously on the same membrane for each experi-
ment followed striping and reprobing of the membrane
allowing us to additionally look at specificity in our model
(Fig. 4d–x compare SU6656 (e, l, and s), shRNA FAK (f,
m, and t), FTI (g, n, and u), wortmannin (h, o, and v),
GF109203X (i, p, and w), and IPA3 (j, q, and x)).
AKT. Basal AKT activity was decreased by shRNA
IGF-IR (Fig. 4a and Supp. Info. Fig. 3a) supporting
autocrine signaling in schwannoma. Src inhibitor
SU6656 (4 lM) (Sakai et al., 2010) and PKC inhibitor
GF109203X (5 lM) (Duggan et al., 2007) (Fig. 4d,e,i),
did not inhibit IGF-I (100 ng/mL)-stimulated AKT phos-
phorylation. Additionally, FAK knock down with shRNA
(Supp. Info. 3b) did not decrease IGF-I-mediated AKT
activity (Fig. 4d,f and Supp. Info. Fig. 3b). Ras inhibitor
FTI 277 (30 lM) (Kim et al., 2010) and PI3K inhibitor
wortmannin (1 lM) strongly inhibited AKT phosphoryla-
tion (Fig. 4d,g,h). PAK inhibitor IPA3 (20 lM), but not
the structurally related control compound Pir3.5 (data
not shown), significantly inhibited IGF-I-mediated AKT
activation (Fig. 4d,j).
ERK1/2. Basal ERK1/2 activity is decreased by
shRNA IGF-IR (Fig. 4b and Supp. Info. Fig. 3a) support-
ing autocrine signaling in schwannoma. SU6656 (4 lM)
(Fig. 4k,l), shRNA for FAK (Fig. 4k,l and Supp. Info.
Fig. 3b), FTI-277 (30 lM) (Fig. 4k,n), wortmannin (1
lM) (Fig. 4k,o) and GF109203X (5 lM) (Fig. 4k,p)
(Toullec et al., 1991) strongly inhibited IGF-I-mediated
ERK1/2 activation. IPA3 (20 lM), had no effect on IGF-
I-mediated ERK activity (Fig. 4k,q).
JNK. Basal JNK activity was decreased by shRNA
IGF-IR (Fig. 4c and Supp. Info. Fig. 3a) supporting auto-
crine signaling in schwannoma. SU6656 (4 lM) (Fig.
4r,s), FAK shRNA (Fig. 4r,t and Supp. Info. Fig. 3b), FTI
277 (30 lM) (Fig. 4r,u), wortmannin (1 lM) (Fig. 4r,v) and
GF109203X (5 lM) (Fig. 4r,w) strongly inhibited IGF-IR-
mediated JNK phosphorylation. IPA3 (20 lM), but not
control compound Pir3.5 (data not shown), significantly
inhibited IGF-IR mediated JNK activation (Fig. 4r,x).
IGF-IR-mediated AKT, ERK1/2, and JNK activation
was inhibited by Ras inhibitor FTI (30 lM) used at the
same concentration as in a previous article on PDGFR
which inhibited Ras activity but not PDGFR-mediated
signaling (Ammoun et al., 2008). In summary, IGF-IR-
mediated activation of ERK1/2 and JNK engages Src/
FAK/Ras/PI3K/PKC. AKT activation involved Ras/PI3K
pathway but not Src/FAK (Wymann et al., 2003). PI3K
acts as a convergence point for ERK1/2, AKT, and JNK
cascades. PAK seems not involved in ERK1/2 activation
but its inhibition decreases AKT and JNK activity after
IGF-I stimulation (Fig. 7). An autocrine effect of IGF-I is
observed as shRNA for IGF-IR decreases basal (nonsti-
mulated with recombinant IGF-I) activity of AKT,
ERK1/2, and JNK, suggesting that autocrine levels of
IGF-I keep the base line activity of those kinases con-
stantly elevated.
In the studies dissecting the IGF-I-mediated signaling
pathways in human primary schwannoma cells, tumors
from three different patients were used. No discrepan-
cies were observed when comparing the results from dif-
ferent patients.
IGFI-R Activation Increases Proliferation and
Cell–Matrix Adhesion of Schwannoma Cells
Proliferation
In schwannoma cells, IGF-I (100 ng/mL) and IGF-II
(100 ng/mL) increased the number of proliferating cells
Fig. 3. Activation of IGF-I-mediated signaling pathways in human
primary schwannoma cells. (a–c) IGF-I (100 ng/mL, 5 min) potentiates
FAK phosphorylation at Tyr925 but not Tyr397 or Tyr861. (d–g) IGF-I
(100 ng/mL, 5 min) stimulates Src, ERK1/2, AKT, and JNK phosphoryl-
ation (n 5 3). In all experiments, data are normalized to basal (nonsti-
mulated) and corrected to the loading control RhoGDI. Levels of total
FAK, Src, ERK1/2, AKT, and JNK are not changed on short term (5
min) stimulation with 100 ng/mL IGF-I. ns (not significant): P > 0.05;
*: P < 0.05; **: P < 0.01; ***: P < 0.001. In figures, mean 6 SEM is
given.
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Fig. 4. Dissection of IGF-I-mediated signaling pathways in human
primary schwannoma cells. AKT, ERK1/2, and JNK pathways were an-
alyzed using shRNA IGF-IR, Src inhibitor SU6656, shRNA FAK, PI3K
inhibitor wortmannin, Ras inhibitor FTI-277, PKC inhibitor
GF109203X, and PAK inhibitor IPA3 at established concentrations. (a–
c) shRNA IGF-IR decreases basal activity of AKT (n 5 3), ERK1/2 (n 5
3), and JNK (n 5 3). (d–j) AKT pathway is dependent on Ras (n 5 3),
PI3K (n 5 3), and PAK (n 5 3), and independent of Src (n 5 3), FAK (n
5 3), and PKC (n 5 3). (k–q) ERK1/2 and (r–x) JNK pathways involve
Src (n 5 3)/FAK (n 5 3)/Ras (n 5 3)/PI3K (n 5 3)/PKC (n 5 3). (k and
q) ERK1/2 is independent, and (r and x) JNK dependent of PAK. Cells
were starved for 24 h; SU6656, wortmannin and GF109203X were
added 40 min before stimulation. IPA3 was added 10 min and FTI-277
24 h before stimulation. Dotted lines display noninhibited IGF-I
response (100%). In (a)–(c), the data are normalized to basal mock
shRNA and in (d), (k), and (r) to IGF-I max response (100%).
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Fig. 5. IGF-IR-mediated proliferation, survival of human primary
schwannoma cells. (a) Compared with basal, IGF-I and IGF-II stimu-
late schwannoma proliferation (BrdUrd) equally, but less than full
growth medium (GFM). (b–e) Basal proliferation is decreased by
shRNA IGF-IR (n 5 3), IGF-IR inhibitor PPP (5 lM; BrduUrd method,
n 5 3) and (1 lM; DAPI method, n 5 3), and monoclonal antibody
R1507 (1 lM, n 5 3). (b–e) IGF-I-mediated proliferation is inhibited by
IGF-IR inhibitors PPP (1 lM) and R1507 (0.015625–0.5 lg/mL). (f and
g) JNK inhibitor SP600125 (n 5 3) or JBD of JIP-1(n 5 3), MEK1/2 in-
hibitor U0126 (n 5 3), Src inhibitor SU6656 (n 5 3), PI3K inhibitor
wortmannin (n 5 3), Ras inhibitor FTI-277 (n 5 3), and shRNA for
FAK (n 5 3) inhibited IGF-IR-mediated proliferation. (h) A 24 h incu-
bation with mTor/PI3K inhibitor BEZ-235 (100 nM, n 5 3) inhibits
IGF-I-mediated schwannoma proliferation. (i) A 4 days incubation of
schwannoma cells with BEZ-235 (100 nM) decreases basal proliferation
with no effect on cell viability. Cell culture medium was changed to se-
rum-free DMEM medium and inhibitors were added 30 min before 24 h
or 4 days incubation with/or without recombinant IGF-I 100 ng/mL.
For expression of the JBD of JIP-1, schwannoma cells were infected
with JBD-expressing adenovirus for 24 h. (j) AKT-in (25 lM, n 5 3)
inhibits phosphorylation of AKT, but not, (k) ERK1/2 (n 5 3). (l) AKT
is not involved in IGF-I mediated proliferation. Cells were treated with
AKT-in (25 lM) for 12 h before incubation with IGF-I (100 ng/mL) for
24 h in serum-free DMEM medium. (m) AKT-in (50 lM, n 5 3), but not
the structurally related control compound ‘‘mock’’ inhibit schwannoma
viability. MEK1/2 inhibitor U0126 (40 lM, n 5 3) and JNK inhibitor
SP600125 (40 lM, n 5 3) do not affect schwannoma viability. ns (not
significant): P > 0.05; *: P < 0.05; **: P < 0.01; ***: P < 0.001. In fig-
ures, mean 6 SEM is given. In (e), white bars represent basal nonsti-
mulated cells, black bars IGF-I stimulated cells without inhibitor, gray
bars IGF-I stimulated cells treated with the inhibitor in left panel or
nonstimulated cells treated with the inhibitor right panel. Proliferation
at 0 lg/mL R1507 is without IGF stimulation, 0.015625 lg/mL is the
first data point with stimulation. We have included unstimulated in
most of our graphs as showing that growth factor stimulation works is
an important control in each experiment.
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(BrdUrd, Fig. 5a). As IGF-I and IGF-II act through the
same receptor IGF-IR, we concentrated on IGF-I-medi-
ated proliferation using inhibitors described above. In
addition to DAPI, we used BrdUrd staining which is
more sensitive method.
Basal proliferation (nonstimulated) of schwannoma
cells was decreased by shRNA IGF-IR (Fig. 5b), 5 lM
IGF-IR inhibitor PPP (Ohshima-Hosoyama et al., 2010)
(Fig. 5c, DAPI), 1 lM PPP (Girnita et al., 2004) (Fig. 5d,
BrdUrd), and by a monoclonal antibody against IGF-IR ,
currently in Phase I clinical trials, R1507 at 1 lg/mL
(Fig. 5e right panel) (Gong et al., 2009; Kolb et al., 2010;
Kurzrock et al., 2010). These data further support
an autocrine loop in human primary schwannoma
cells. IGF-I-stimulated (100ng/mL, Fig. 5e left panel)
proliferation was decreased to the basal levels by IGF-
IR inhibitors PPP (1 lM) and R1507 (0.125 lg/mL),
lower concentrations (0.015625 lg/mL) was not effective
and 0.03125 lg/mL decreased IGF-I-mediated prolifera-
tion only partially (Fig. 5c,e), MEK1/2 inhibitor U0126
(10 lM) (Fig. 5f third panel) and JNK inhibitor
SP600125 (10 lM) (Bennett et al., 2001) (Fig. 5f first
panel) suggesting ERK1/2 and JNK for being mitogenic
for schwannoma on IGF-IR stimulation. JBD-GFP a
negative regulator of JNK was also effective in the inhi-
bition of IGF-I-mediated proliferation (Fig. 5f second
panel). shRNA FAK decreased IGF-I-mediated schwan-
noma proliferation (Fig. 5g). Because Src, Ras, and PI3K
are involved in IGF-IR-mediated ERK1/2 and JNK acti-
vation, we tested whether inhibitors of any of those
kinases inhibit IGF-I-mediated proliferation. Src inhibi-
tor SU6656 (1 lM), Ras inhibitor FTI277 (30 lM)
(Ammoun et al., 2008; Kim et al., 2010), and PI3K inhibi-
tor wortmannin (1 lM) (Rexhepaj et al., 2010; Shi et al.,
2001) inhibited IGF-I-mediated proliferation of schwan-
noma cells (Fig. 5f). As PI3K cross talks to ERK1/2, AKT,
and JNK (Figs. 4 and 7), we tested also dual mTor/PI3K
small molecular inhibitor BEZ-235 (100 nM) which inhib-
ited IGF-IR-mediated schwannoma proliferation (24 h
treatment) (Fig. 5h). Basal schwannoma proliferation
was decreased after 4 days’ treatment with BEZ-235 (100
nM) without affecting cell viability (Fig. 5i).
None of the inhibitors was toxic at concentrations used
(data not shown), and Src inhibitor SU6656, Ras inhibitor
FTI277, PI3K inhibitor wortmannin, and MEK1/2 inhibi-
tor U0126 were already validated in schwannoma model
(Ammoun et al., 2008, 2011). AKT inhibitor peptide (AKT-
in) (25 lM) which inhibited AKT by 40% (Fig. 5j) but not
ERK (Fig. 5k) did not decrease IGF-I-mediated prolifera-
tion (Fig. 5l). Thus, IGF-I-mediated proliferation recruits
JNK and ERK1/2 but not AKT (Figs. 5f and 7).
Cell survival
Three days treatment with 50 lM AKT-in decreased
schwannoma cell viability compared with AKT-in mock
(Fig. 5m) (Hiromura et al., 2004). Neither MEK1/2 in-
hibitor U0126 (40 lM) nor JNK inhibitor SP600125 (40
lM) (Momcilovic et al., 2008) affected schwannoma cells’
viability (Fig. 5m), suggesting that AKT but not ERK1/2
or JNK is a prosurvival in schwannoma.
Adhesion
Both IGF-I (100 ng/mL, 3 h) and IGF-II (100 ng/mL, 3
h) induced cell–matrix adhesion in schwannoma cells
(Fig. 6a). This was not pronounced as with GFM but
reached up to 50% (Fig. 6a). shRNA IGF-IR decreased
basal (nonstimulated) adhesion of schwannoma cells
suggesting autocrine signaling (Fig. 6b).
IGF-IR inhibitor PPP (1 lM) and MEK1/2 inhibitor
U0126 (10 lM) completely inhibited IGF-I-mediated
adhesion whereas JNK inhibitor SP600125 (10 lM) had
no effect (Fig. 6c second panel). Src inhibitor SU6656
(4 lM) and PI3K inhibitor wortmannin (1 lM) (Fig. 6c
fourth and fifth panels) completely inhibited IGF-I-medi-
ated adhesion of schwannoma cells.
In summary, this article demonstrates the overexpres-
sion and activation of IGF-IR in human schwannoma
(Fig. 7). IGF-IR ligands IGF-I and IGF-II are also over-
expressed and released (Fig. 7) leading to increased acti-
vation of FAK, Src, ERK1/2, JNK1/2, and AKT (Fig. 7).
IGF-IR-mediated activation of ERK1/2 engages Src/FAK/
Ras/PI3K/PKC, JNK Src/FAK/Ras/PI3K/PKC/PAK and
AKT Ras/PI3K/PAK pathways (Fig. 7). ERK1/2 mediates
IGF-IR stimulated proliferation and adhesion of schwan-
Fig. 6. IGF-IR-mediated cell matrix adhesion of human primary
schwannoma cells. (a) IGF-I (100 ng/mL, n 5 9) and IGF-II (100 ng/
mL, n 5 3) stimulate schwannoma cell–matrix adhesion equally, but
less than full growth medium (GFM, n 5 8). (b) Basal (nonstimulated)
adhesion decreases on IGF-IR knock down with shRNA (n 5 3). (c)
IGF-I-mediated adhesion decreases on treatment with IGF-IR inhibitor
PPP (1 lM, n 5 3), JNK inhibitor SP600125 (10 lM, n 5 6), MEK1/2
inhibitor U0126 (10 lM, n 5 3), Src inhibitor SU6656 (4 lM, n 5 3),
and PI3K inhibitor wortmannin (1 lM, n 5 5) indicating dependence
on the ERK1/2 but not JNK pathway involving Src and PI3K. The cells
were starved for 24 h, detached, preincubated with inhibitors for 30
min, stimulated with IGF-I (100 ng/mL), seeded again, and incubated
for 3 h. In upper left and right panels, the data are normalized to the
basal (nonstimulated) values. In bottom panel, the data are normalized
basal mock shRNA. ns (not significant): P > 0.05; *: P < 0.05; **: P <
0.01; ***: P < 0.001. In figures, mean 6 SEM is given.
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noma cells, JNK1/2 promotes adhesion and AKT sur-
vival (Fig. 7). IGF-IR-mediated pathological changes
were normalized using a monoclonal antibody targeting
IGF-IR R1507 and IGF-IR shRNA (Fig. 7). PI3K is a
common kinase for IGF-IR mediated ERK1/2, JNK1/2,
and AKT activation and can be successfully targeted by
small molecule inhibitor BEZ-235 (Fig. 7).
DISCUSSION
We demonstrate strong overexpression of IGF-IR, and
ligands IGF-I/IGF-II triggering activation of ERK1/2,
JNK, and AKT pathways and show relevance for
increased proliferation, adhesion, and survival of human
primary schwannoma cells. We dissected downstream
signaling cascades to identify potential therapeutic tar-
gets and test two small molecule inhibitors.
IGF-IR overexpression is in line with previously
reported findings of membrane accumulation and over-
expression of growth factor receptors in merlin-deficient
cell lines (Lallemand et al., 2009). We show activation of
IGF-IR in schwannoma cells and human schwannoma
tissues compared with Schwann cells. Strong glycosyla-
tion increases IGF-IR attachment to the cell membrane
resulting in decreased internalization and degradation
(Carlberg and Larsson, 1996). Unexpectedly, IGF-IR gly-
cosylation is equal in schwannoma and Schwann cells
suggesting that IGF-IR activity in schwannoma cells
must involve other mechanisms such as disruption of
cell-to-cell contact allowing receptors to recycle to the
cell surface which has shown to be inhibited by merlin
(Flaiz et al., 2008; Lallemand et al., 2009; Li et al.,
2010). IGF-IIR regarded as a tumor suppressor (Hebert,
2006) is equally expressed in schwannoma and Schwann
cells. We show overexpression and release of IGF-I and
IGF-II, relevant in Schwann cell biology, from schwan-
noma cells compared with Schwann cells suggesting
that autocrine signaling is relevant in schwannoma
development acting in concert with autocrine IGF-I and
IGF-II. The autocrine circuit is demonstrated by the
negative regulation of basal proliferation, adhesion, and
signaling pathways by shRNA IGF-IR and further sup-
ported by proliferation assays with IGF-IR inhibitors
PPP and R1507. Immunohistochemistry showed that
IGF-IR, IGF-I, and IGF-II, in addition to the cytoplasm,
localizes to the nucleus in schwannoma tissues which
has been shown in other cells to promote tumor develop-
ment (Schedlich et al., 2003; Sehat et al., 2010). To
understand the targetability of IGF-IR signaling in
schwannoma, we investigated different signaling path-
ways activated in schwannoma cells on IGF-IR stimula-
tion. Despite replacing cell culture medium with fresh
medium just before stimulation with exogenous IGF-I
and IGF-II, we cannot exclude a small additional auto-
crine effect at least in the longer term experiments.
However, we show clear stimulation of a variety of path-
ways due to IGFI/II. We show increased FAK phospho-
rylation at the Src phosphorylation site Tyr925 on cell
stimulation with IGF-I (100 ng/mL, 5 min). Phosphoryl-
ation of FAK at its autophosphorylation site Tyr397,
known to be triggered by b integrins (Zhao and Guan,
2009) strongly overexpressed in human schwannoma
(Utermark et al., 2003b), is not potentiated further by
IGF-I but likely is basally high which is necessary for
further phosphorylation at Tyr925 (Zhao and Guan,
2009). The phosphorylation of FAK at Tyr925 is impor-
tant for its coupling to Ras/Raf/MEK/ERK cascade up-
regulated in schwannoma (Ammoun et al., 2008).
Indeed, we show that FAK shRNA blocked IGF-I-trig-
gered ERK activation in schwannoma cells. Using vari-
ous inhibitors established in our model (Ammoun et al.,
2008, 2011), we show that ERK and JNK pathways
involve Src/FAK/Ras/PI3K and PKC. AKT is activated
via Ras/PI3K pathway (Fig. 7).
We demonstrate that IGF-I and IGF-II are mitogenic
for schwannoma cells suggesting that, in addition to
PDGF (Ammoun et al., 2008) and heregulin (Ammoun
et al., 2010a), IGF-I and IGF-II are relevant in schwan-
noma. IGF-I-mediated increase in schwannoma prolifer-
ation engages JNK and ERK1/2 but not AKT which is
prosurvival. This supports a previous demonstration of
decreased viability of primary vestibular schwannoma
cells when treated with phosphoinositide-dependent ki-
Fig. 7. Postulated IGF-IR-mediated signaling pathways in human
primary schwannoma cells. In schwannoma, IGF-IR and integrins are
overexpressed and activated. IGF-I and IGF-II are upregulated and
released. Stimulated IGF-IR activates Src and Ras. Active Src phophor-
ylates FAK, already autophosphorylated at Tyr397 via integrins, at the
additional tyrosine site Tyr925 important for coupling active Ras to
Raf/MEK1/2/ERK1/2 and MEKK1/MEKK4/7/JNK pathways. Ras, acti-
vated PI3K, C-Raf, and MEKK1 result in ERK1/2, AKT, and JNK acti-
vation. PAK contributes to JNK and AKT but not ERK1/2 activation.
FAK couples to JNK and ERK1/2 but not AKT pathways. IGF-IR-
stimulated ERK, JNK, and AKT share a common targetable kinase
PI3K which is inhibited by mTor/PI3K inhibitor BEZ-235. ERK1/2 and
JNK are responsible for increased growth, ERK1/2 for enhanced cell–
matrix adhesion and AKT for survival of schwannoma cells. IGF-I-
mediated schwannoma proliferation was successfully targeted by IGF-
IR inhibitor R1507 (Phase I). [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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nase-1 inhibitor OSU-03012 (Lee et al., 2009). However,
the inhibition of AKT decreases survival only partially
suggesting that other prosurvival pathways may be
active, making cells not addicted to AKT. The inhibition
of AKT leads to decreased cell viability only when AKT-
in are used at high concentrations for 3 days. Inhibition
of AKT had no effect on schwannoma proliferation
which could be due to a previously described positive
feedback toward increased expression of IGF-IR and
ErbB3 (Chandarlapaty et al., 2011). We also show that
pathological schwannoma cell–matrix adhesion engaging
IGF-I involves Src/PI3K/ERK1/2 pathway. In summary
(Fig. 7), we suggest that IGF-IR mediates proliferation
and adhesion involving different pathways, ERK1/2 and
JNK for proliferation and ERK1/2 for adhesion. AKT
regulates cell survival, previously shown to be enhanced
in schwannoma cells (Utermark et al., 2005).
From this data and published data, it seems likely that
inhibition of schwannoma growth would possibly require
inhibition of several targets. Our results support two pos-
sible treatment options: (1) combinational therapy target-
ing IGF-IR and PDGFR; PDGFR inhibitors Sorafenib and
Nilotinib (currently in Phase 0 clinical trials on NF2
patients) (Ammoun et al., 2008, 2011) and IGF-IR inhibi-
tor R1507 (current data) have been already validated in
schwannoma. (2) Therapy targeting a common molecule
downstream of overactivated receptors. PI3K is such
therapeutic target which has been previously shown to be
involved in PDGFR-mediated ERK1/2 and AKT activa-
tion (Ammoun et al., 2008) and, as shown in this study,
provides a common link for IGF-I-mediated ERK1/2, AKT
and JNK pathways (Fig. 7). Here, we successfully used
mTor/PI3K inhibitor BEZ-235 to significantly decrease
basal and completely inhibit IGF-I-mediated schwan-
noma proliferation. As the inhibition of PI3K would in-
hibit all currently known pathways activated in schwan-
noma (Ammoun et al., 2008), the development of acquired
resistance via compensation mechanisms would be negli-
gible. As schwannomas are located outside of blood–brain
barrier, drug delivery to the tumor should not be prob-
lematic. We suggest that results from using our human
in vitro model for schwannoma will allow us to speed up
bench to bed transition and reprofile drugs, directly in
Phase 0 clinical trials.
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